# Amber Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amber-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.amber-tx.com
- Total disclosed funding: $101M
- Latest round: Series A (Jun 9, 2024)
- Investors on record: 7

## About

Based in London, UK, and founded in 2021, Amber Therapeutics Limited provides next-generation, intelligent bioelectrical therapies. The company was founded by Aidan Crawley (CEO) and Tim Dension. In January 2023, raised an amount of Seed funding from investors 8VC, Oxford Sciences Enterprises, and the UK Technology Strategy Board.

The company develops therapies such as bioelectrical therapies in order to improve clinical outcomes for patients with functional impairments of the peripheral nervous system. The firm therapy includes Amber-UI a fully implantable closed-loop bioelectrical therapy that is now in clinical development with the goal of treating urge and mixed urine incontinence (UI).

## Funding rounds

- Series A, Jun 9, 2024, $100M — New Enterprise Associates, F-Prime Capital, Lightstone Ventures, Oxford Sciences Enterprises, 8VC, Intuitive Ventures
- Seed, Jun 18, 2021, $1.4M — UK Technology Strategy Board, Oxford Sciences Enterprises, 8VC

## Investors

- UK Technology Strategy Board — Seed
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed, Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A
- Intuitive Ventures (https://capitalatlas.ai/funds/intuitive-ventures) — Series A